BAX and esophageal squamous cell carcinoma: In esophageal squamous cell carcinoma (ESCC), BI2536, an inhibitor of polo-like kinase 1(PLK1), was found to activate caspase-3 and BAX in combination with cisplatin, resulting in GSDME disruption and increased DNA damage.